24 results about "Host protein" patented technology

The invention relates to a high-temperature-resistant feruloyl esterase liquid as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) constructing a reaction system: suspending recombinant microorganism thalli for expressing high-temperature-resistant feruloyl esterase in a buffer solution with the pH value of 7.0-9.0; (2) ultrasonic cracking and thermal purification: heating the reaction system to 70-85 DEG C under the condition of ultrasonic crushing, and keeping the temperature for 1-8 hours; carrying out structural destruction on the microbial thalli by utilizing ultrasound so as to release intracellular high-temperature-resistant feruloyl esterase, and carrying out denaturation and precipitation on host impure protein by utilizing the thermal stability difference between the high-temperature-resistant feruloyl esterase and the host impure protein; after the high-temperature-resistant feruloyl esterase is subjected to heat treatment in the step (2), the catalytic activity is kept at the temperature of 60 DEG C or above; and (3) obtaining an enzyme solution, namely centrifuging the reaction body fluid subjected to the ultrasonic treatment and the heat treatment in the step (2), and collecting supernate, so as to obtain the high-temperature-resistant feruloyl esterase solution.

The application is a virus and host protein interaction prediction method based on a densely connected convolutional network, comprising the following steps: step 1, preprocessing data; step 2, using a Skip-Gram model in Word2Vec and One-Hot encoding to obtain embedding vectors of amino acids; step 3, constructing a densely connected convolutional network for feature extraction according to a word embedding matrix of the protein; step 4, obtaining average RPM-PSSM feature descriptors through a PSSM feature matrix; step 5, constructing a fully connected neural network for feature extraction according to the feature descriptors; step 6, performing feature fusion through a concatenate operation, and finally using the trained model for prediction. The application performs feature extraction on different features, contains protein evolution information and physicochemical properties, local key information and long-range dependence in the sequence, and better improves the prediction accuracy.

The invention belongs to the field of biology, and particularly relates to construction of a recombinant Seneca virus strain with Seneca virus 2B protein translation block site mutation. The 26th lysine (K) of the 2B protein is found to be a key site for inhibiting the translation of the host protein for the first time, and after the 26th K of the 2B protein is mutated into the alanine (A), the translation retardation phenomenon of the host protein is obviously weakened; secondly, the 26th K of the 2B protein is mutated into A to construct infectious clone, and the recombinant Seneca virus strain rSVA-2B K26A with 2B protein translation retardation site mutation is successfully rescued and obtained, compared with wild type SVA, after the rSVA-2B K26A infects host cells, the translation retardation phenomenon of the host cells is weakened, the expression level of host antiviral inflammatory cytokines is enhanced, and the expression level of the recombinant Seneca virus strain rSVA-2B K26A is improved. The Seneca virus vaccine strain can be used as a potential vaccine candidate strain, and a foundation is laid for developing a novel prevention and control strategy aiming at the Seneca virus.

Proteases of Group IV (+)ssRNA viruses were found to act on a human sequences in addition to the viral sequences. The identity of the cleavable human sequences is disclosed. Detection of these sequences can act as a diagnostic of infection. It is contemplated that these findings could be employed to facilitate post-translational silencing at the level of protein (e.g., removal of existing proteins), thus serving as a protein analog to CRISPR / Cas9 and RNAi / RISC, and further to enable sequence-specific silencing of host functions without the modification of the host genome.

The invention discloses a targeted nutrient source mining method based on beef cattle intestinal type-host gene interaction, particularly relates to the field of biological information data processing, and is used for solving the problems that existing nutrient source development lacks molecular mechanism verification and is poor in targeting. The method comprises the following steps: firstly, dividing nutrition-associated intestinal types based on microbiome and transcriptome data, and constructing a co-expression network to screen host co-expression specific genes driven by the specific intestinal types; then, establishing a flora metabolite ligand set and host protein receptor model, executing molecular conformation search and Gibbs free energy calculation, and screening high-activity targeting effect factors based on physical affinity; and finally, traversal matching and quantitative screening are carried out on the natural raw material liquid chromatography-mass spectrometry data by using the targeted effect factors, and a targeted nutrition source recommendation list aiming at the specific intestine type is generated. According to the method, multi-omics correlation analysis and molecular thermodynamics verification are fused, and an accurate development closed loop from micromechanism analysis to macroscopic raw material matching is constructed.

The invention discloses a nucleic acid molecule for inhibiting Zika virus, a pharmaceutical composition containing the nucleic acid molecule and application. The invention develops an anti-virus strategy for realizing the target host protein based on the RNA structure by changing the bottom-layer anti-virus logic. The MSI1 binding site in the nucleic acid molecule is highly conserved in all Zika virus strains, and the nucleic acid molecule has wide applicability. Meanwhile, the nucleic acid molecule can target an MSI1 high-expression region (namely virus-susceptible tissue), the problem of poor tissue specificity in existing delivery is solved, and the nucleic acid molecule is higher in targeting property, so that the nucleic acid molecule can cope with nervous system infection and pregnancy infection. In addition, the sequence design is relatively simple, and based on natural RNA sequence optimization, the modification demand is reduced, the natural affinity is high, and the chemical modification dependence is greatly reduced.

The invention discloses application of carfilzomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of nipah virus M protein, the carfilzomib is used for inhibiting a host proteasome path, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and the effect is good. At present, most of research and development of virus medicines and vaccines are designed or modified aiming at viruses, a new thought is provided for research and development of medicines and vaccines in the future, and a new application is also provided for Carfilzomib.

The invention discloses an affinity purification process for human serum albumin and a DARPin dimer ligand, the DARPin dimer comprises a first DARPin monomer and a second DARPin monomer, and the first DARPin monomer and the second DARPin monomer both have a four-segment structure of N-cap, IR1, IR2 and C-cap; the amino acid sequences of the first DARPin monomer and the second DARPin monomer are selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 in a sequence list; the amino acid sequences of the first DARPin monomer and the second DARPin monomer have at least 90%-98% sequence identity with any one amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5, and maintain specific binding activity to human serum albumin. According to the present invention, through the N-cap, IR1, IR2 and C-cap four-segment type DARPin dimer design, the convection column matrix is optimized so as to obtain the novel ligand with high affinity and high specificity on the human serum albumin, and the non-specificity of the host protein and the similar structure impurities is significantly reduced;

Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and / or nasal administration of the pharmaceutical composition.

This invention discloses a multilocular echinococcosis larva. In Preparation method of -6B protein and its application in the preparation of anti-host inflammatory agents. Through protein structure modeling and molecular docking technology, the preparation method was confirmed. In -6B can bind with high affinity to a key subunit of the host 26S proteasome, affecting the assembly of the proteasome in the host and thus interfering with the activity of the NF-κB signaling pathway, thereby regulating the host inflammatory response. Animal experiments have shown that recombinant... In -6B intervention significantly alleviated colonic damage in mice with inflammatory bowel disease, regulated the expression levels of pro-inflammatory and anti-inflammatory factors, and improved the survival rate of septic mice, with no obvious toxic side effects observed. This invention opens up a new pathway for developing anti-inflammatory agents using natural molecules that interact with the parasite's immune system, and provides a novel mechanism of action and biosafety for anti-host inflammatory biological agents, showing great potential for application in the prevention and treatment of inflammatory diseases in humans and livestock.

This invention provides rice OsLHCA3 The uses of genes and their application in breeding virus-resistant rice, the above OsLHCA3 The nucleotide sequence of the gene is shown in SEQ ID NO.1. This invention utilizes transgenic technology to achieve overexpression in rice. OsLHCA3 This gene can significantly enhance rice's resistance to RSV. The mechanism lies in... OsLHCA3 The protein recruits the RSV motility protein NSvc4 to chloroplasts, interfering with the interaction between NSvc4 and the host protein OsREM1.4, thereby inhibiting the intercellular motility function of NSvc4. This invention provides a new gene resource for RSV-resistant rice breeding and has important application prospects.

This invention relates to the field of biotechnology, specifically to a method for elucidating the interaction complex between the BTVNS2 protein and host cells. The method involves constructing an initial list of host proteins through cross-validation using affinity purification-mass spectrometry and biotinylate proximity labeling-mass spectrometry. Weighted scoring and ranking are then performed based on quantitative mass spectrometry data and functional relevance. Binding characteristics are validated and quantified intracellularly and extracellularly using immunoprecipitation and biophysical techniques, respectively. The complex is assembled in vitro, and its high-resolution three-dimensional structure is resolved using single-particle cryo-electron microscopy. This invention addresses key problems in existing technologies, such as incomplete capture of interacting proteins, high false-positive rates, blind functional screening, and difficulty in obtaining samples suitable for high-resolution structural analysis due to reliance on single methods. It systematically identifies key host factors and ultimately reveals the precise structure of the interaction interface at the atomic level, providing a foundation for understanding viral replication mechanisms and developing antiviral strategies.

The invention discloses an affinity chromatography method for purifying human growth hormone and a DARPin dimer ligand. The DARPin dimer comprises a first DARPin monomer and a second DARPin monomer which are connected through a connecting peptide or a disulfide bond; each DARPin monomer is provided with a four-section type structure of an N-cap, a first internal repeated module IR1, a second internal repeated module IR2 and a C-cap; the amino acid sequence of the DARPin monomer is selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 in a sequence list, and the amino acid sequence of the DARPin monomer has 90%-98% sequence identity with any amino acid sequence selected from the list. According to the present invention, through the design of the DARPin dimer ligand having the N-cap, the first internal repeating module IR1, the second internal repeating module IR2 and the C-cap four-segment structure, and the directed random mutation of the IR1 / IR2 region, the novel ligand having high affinity and high specificity on the human growth hormone is obtained, and the non-specific binding of the host protein and the structure-similar impurities is significantly reduced;

The invention belongs to the field of marine gene biological medicine, and particularly relates to siRNA of host metabolic protein and targeted protein interacting with main capsid protein of decapod iridovirus 1 in litopenaeus vannamei and application of the siRNA in inhibition of virus replication. According to the invention, through yeast two-hybrid screening, the host protein which is subjected to specific interaction with the main capsid protein of DIV1 is identified and obtained from litopenaeus vannamei, and the interaction relationship is verified through an in-vitro interaction experiment. Further RNA interference experiment results show that siRNA targeting the host protein can stably play a role in gene knock-down in litopenaeus vannamei bodies, and the knock-down effect can be maintained under the DIV1 infection condition. On the basis, the detection result of the virus load prompts that the replication process of the DIV1 in the litopenaeus vannamei body can be influenced by regulating and controlling the expression level of the host protein.

The application discloses a construction method of a human adenovirus type 4 protein V knockout mutant strain and application thereof, and belongs to the technical field of biotechnology. The application precisely knocks out a protein V coding sequence in a human adenovirus type 4 full-genome infectious clone by means of a Red / ET homologous recombination system combined with a ccdB reverse screening technology, and obtains a recombination plasmid pBR322-Ad4-△V-EGFP which is clear in genetic background and highly homozygous in sequence. After the plasmid is transfected into HEK-293 cells, the human adenovirus type 4 protein V knockout mutant strain obtained exhibits a typical “replication-deficient” phenotype: although a particle containing a viral genome can be packaged, the physical titer (4.76×10 6 copies / μL) of the particle is about one order of magnitude lower than that of a wild type, and the progeny virus completely loses secondary infection ability. Transcriptome analysis reveals that the deletion mutation can specifically down-regulate a host proteasome pathway and activate a natural immune response. The mutant strain is high in safety and strong in immunogenicity, and can be used as an ideal attenuated vaccine carrier or a gene therapy tool.

The present invention provides live attenuated vaccines for the prophylactic treatment of Chikungunya virus infections. The vaccines comprise a genetically modified Chikungunya virus that has a reduced replication capacity due to a mutation or deletion in the R5 region of the hypervariable domain of nsP3, a nonstructural protein that interacts with host factors. The inventors have indeed discovered that the R5 region of the hypervariable domain of nsP3, a nonstructural protein that interacts with host factors, is critical for CHIKV replication and pathogenesis. Specifically, the inventors have shown that the R5 region is required for the interaction of nsP3 with FHL1, BIN1 and CD2AP, three host proteins that are involved in the regulation of actin cytoskeleton and membrane trafficking. These host proteins are expressed in muscle and joint tissues, which are the main targets of CHIKV infection and inflammation. By mutating or deleting the R5 region of nsP3, the inventors have generated a genetically modified CHIKV (CHIKV-ΔR5) that has a reduced replication capacity and virulence compared to the WT virus. Moreover, the inventors have demonstrated that CHIKV-ΔR5 is able to elicit a strong neutralizing antibody response and protect mice from lethal challenge with WT virus. The present invention also provides screening methods for identifying test substances that are capable of inhibiting the interaction between nsP3 and FHL1, CD2AP and BIN1, wherein the selected test substances would be suitable for the treatment of CHIKV infections.

The application of TAB2 protein in rabies treatment target spot belongs to the field of biological medicine technology. In order to study the influence of host protein on RABV replication, further study the pathogenic molecular mechanism of RABV, and find new rabies treatment target and drug, the application uses fluorescence quantification, Western Blotting and other methods to study the influence of host protein TAB2 on RABV replication, and finds that TAB2 gene transient knockdown or stable knockdown can inhibit the replication of rabies virus, and further finds that TAB2 protein can be used as a new target for rabies treatment. In addition, the application also finds the structure domain of TAB2 and RABV M interaction and the TAB2 protein promotes RABV replication by activating TAK1-p38 / MAPK signal pathway, and the p38 inhibitor Gossypetin and the TAK1 inhibitor Takinib can be used as potential drugs for treating RABV infection.

The application belongs to the field of genetic engineering, and particularly relates to a construction method and application of a red fluorescent protein labeled recombinant blue tongue virus. The application inserts a red fluorescent protein label sequence (mScarlet3) between 158th and 159th amino acids of a wild type blue tongue virus NS3 protein, and obtains a NS3 labeled recombinant blue tongue virus BTV-1 / NS3-158mScarlet3. Compared with the wild type blue tongue virus, the recombinant NS3 protein can correctly express the red fluorescent protein, but does not affect the replication of the virus, and can be used for expression positioning and dynamic tracking of the NS3 protein in the BTV infected cell, interaction between the NS3 protein and the host protein, BTV neutralization test, antiviral drug screening and gene delivery and the like.

This invention belongs to the field of fish disease resistance gene technology / virology, specifically involving the application of Endoglin as a receptor for grass carp reovirus type II. The in vitro purified recombinant structural proteins VP4 and VP56 of GCRV-II can specifically bind to Endoglin protein; knockdown in sensitive cell lines and overexpression in insensitive cell lines... Endoglin Genes can affect viral load. Furthermore, using rare gudgeon as a model, gene editing technology was employed to... Endoglin Gene knockout was performed, and the results showed that heterozygotes with the knockout of this host protein significantly inhibited GCRV-II infection in rare gudgeon. These results demonstrate that Endoglin is a key receptor for GCRV-II virus infection in grass carp, providing a foundation for disease-resistant breeding in grass carp and offering important reference value for disease-resistant breeding in other farmed fish species.

The invention belongs to the technical field of biological medicines, and discloses application of isochlorogenic acid B in preparation of a medicine for preventing and treating coronavirus pneumonia. It is known that hnRNPA2B1 can specifically recognize virus genetic materials, and the natural immune response to viruses is started. Experiments prove that the isochlorogenic acid B can be combined with hnRNPA2B1 host protein to mediate the virus infection process, the antiviral immune response is affected, lung tissue damage caused by coronavirus infection is effectively relieved, the virus load in lung tissue is reduced, the effect of preventing and treating coronavirus pneumonia is achieved, and the isochlorogenic acid B is good in safety as a natural product.

Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.

The application belongs to the field of marine gene biological medicine, and particularly relates to a host metabolic protein interacting with a major capsid protein of Decapoda iridovirus 1 in Litopenaeus vannamei, siRNA of the target protein and application of the siRNA in inhibiting virus replication. The application identifies and obtains the host protein specifically interacting with the major capsid protein of DIV1 from Litopenaeus vannamei through yeast two-hybrid screening, and verifies the interaction relationship through in-vitro interaction experiment. Further RNA interference experiment results show that the siRNA targeting the host protein can stably play a gene knockdown role in the body of Litopenaeus vannamei, and maintain the knockdown effect under the condition of DIV1 infection. On this basis, the detection results of virus load suggest that by regulating the expression level of the host protein, the replication process of DIV1 in the body of Litopenaeus vannamei can be affected.

The application discloses a targeted nutrient source mining method based on beef cattle intestinal type-host gene interaction, and particularly relates to the field of biological information data processing, and is used for solving the problems of lack of molecular mechanism verification and poor targeting of existing nutrient source development. First, based on the microbiome and transcriptome data, the nutrient-related intestinal type is divided, and the co-expression network is constructed to screen the host co-expression specific genes driven by the specific intestinal type. Then, the model of the group metabolite ligand set and the host protein receptor is established, the molecular conformation search and the Gibbs free energy calculation are performed, and the high-activity targeted effect factor is screened based on the physical affinity. Finally, the targeted effect factor is used for traversing matching and quantitative screening of natural raw material liquid chromatography-mass spectrometry data, and a targeted nutrient source recommendation list for the specific intestinal type is generated. The application combines multi-omics correlation analysis and molecular thermodynamic verification, and constructs a precise development closed loop from micro mechanism analysis to macro raw material matching.

The application discloses application of coenzyme Q10 in preparation of a medicine for resisting new duck reovirus, and belongs to the technical field of veterinary biological products. The application locks a key pathogenic protein sigma C of the new duck reovirus and a host protein COQ6 interacting with the key pathogenic protein sigma C by using a cell model infected by the NDRV and a duckling model; further combining the core role of the COQ6 in a coenzyme Q10 synthesis path, it is found that the coenzyme Q10 can resist the new duck reovirus infection, and a new prevention and treatment strategy is provided for prevention and treatment of the new duck reovirus disease.